SHORT COURSE PROMACE -CYTABOM FOR STAGES II/IV DIFFUSE AGGRESSIVE LYMPHOMA

本研究旨在作为一项试点研究，以测试可行性， 给予标准组合的剂量强度形式的功效 II、III和III期患者的化疗方案ProMACE-CytaBOM IV期弥漫性侵袭性淋巴瘤和III期和IV期滤泡性混合型 淋巴瘤 治疗包括8个2周周期，总计 十六周。 增加了剂量递增方案，大多数患者 都可以升级到三级剂量 到目前为止，已有81 入组研究的可评价患者：69例达到完全缓解 (85%). 有14次复发，都是在短暂的完全性的 缓解。 这些初步结果表明，治疗可以 安全给药，尽管有些患者需要减少剂量。 响应 率与标准ProMACE-CytaBOM相当。

This study was designed as a pilot study to test the feasibility and efficacy of administering a dose-intense version of a standard combination chemotherapy regimen ProMACE-CytaBOM for patients with stages II, III, and IV diffuse aggressive lymphoma and stages III and IV follicular mixed lymphoma. The treatment consists of eight 2-week cycles, for a total of sixteen weeks. A dose escalation schema has been added and most patients are able to be escalated to dose level three. To date, there have been 81 evaluable patients entered on study: 69 have achieved a complete response (85%). There have been 14 relapses, all following short complete remissions. These preliminary results indicate that the treatment can be safely given, though some patients require dose-reductions. Response rates are equivalent to standard ProMACE-CytaBOM.